Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of ABBV-932 in Healthy Adult Subjects

NCT05738850 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05738850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of ABBV-932 in Healthy Adult Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
February 15, 2023
Completion date
May 31, 2024
Enrollment
104 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder (gad), healthy participants